[1]陈 科,陈继军,陈赵乐,等.CPT1C的表达水平与甲基化的关联及其对胃癌预后的影响[J].医学信息,2022,35(18):19-24.[doi:10.3969/j.issn.1006-1959.2022.18.005]
　CHEN Ke,CHEN Ji-jun,CHEN Zhao-le,et al.Correlation Between CPT1C Expression and Methylation and its Effect on Prognosis of Gastric Cancer[J].Journal of Medical Information,2022,35(18):19-24.[doi:10.3969/j.issn.1006-1959.2022.18.005]
点击复制

CPT1C的表达水平与甲基化的关联及其对胃癌预后的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年18期
页码:
19-24
栏目:
论著
出版日期:
2022-09-15

文章信息/Info

Title:
Correlation Between CPT1C Expression and Methylation and its Effect on Prognosis of Gastric Cancer
文章编号:
1006-1959（2022）18-0019-06
作者:
陈 科; 陈继军; 陈赵乐; 等
（解放军空军军医大学第一附属医院急诊科，陕西 西安 710032）
Author(s):
CHEN Ke; CHEN Ji-jun; CHEN Zhao-le; et al.
(Department of Emergency,the First Affiliated Hospital of PLA Air Force Military Medical University,Xi’an 710032,Shaanxi,China)
关键词:
胃癌; 肿瘤基因组图谱; Kaplan-Meier Plotter; DNA甲基化交互可视化数据库; CPT1C
Keywords:
Gastric cancer; The Cancer Genome Atlas; Kaplan-Meier Plotter; DNA methylation interactive visualization database; CPT1C
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2022.18.005
文献标志码:
A
摘要:
目的 探讨CPT1C在胃癌中的表达情况及其可能参与的信号通路。方法 从肿瘤基因组图谱（TCGA）数据库中下载并预处理胃癌数据集的mRNA表达RNA-seq数据及临床预后相关数据，对胃癌组织和正常组织中CPT1C基因进行差异表达分析，并绘制图型。以CPT1C表达量的中位数为界将胃癌患者分为高表达组和低表达组，使用Kaplan-Meier法进行生存分析，探索CPT1C的表达与胃癌患者生存和临床病理特征的关系。同时利用DNA甲基化交互可视化数据库（DNMIVD）分析CPT1C甲基化与基因表达的关系及其与预后的相关性。使用GSEA4.0.1软件进行基因集富集分析，同时进行多GSEA富集分析的图形绘制。结果 CPT1C在胃癌中显著高表达，与癌旁组织的差异具有统计学意义（P=0.003）；删除TCGA胃癌患者中生存时间＜30 d的样本后，共有306例样本，CPT1C高表达患者（n=153）预后更差（P=0.01），且在Kaplan-Meier Plotter数据分析平台中，高表达CPT1C的胃癌患者同样与不良预后相关（P＜0.05）；对TCGA胃癌患者的单因素和多因素回归分析提示，高表达CPT1C与更短的生存相关（P=0.02），CPT1C基因表达与DNA启动子甲基化呈显著负相关（r=-0.33，P=6.60e-10），并且低甲基化与不良预后相关（P=7.53e-03）；GSEA分析结果显示，CPT1C高表达样本富集了ECM受体相互作用、Ca离子信号通路和HEDGEHOG信号通路等相关基因集，而CPT1C低表达样本则富集了剪接体，碱基切除修复和氧化磷酸化等相关基因集。结论 CPT1C可能作为胃癌的独立预后因素，其可能通过参与ECM受体相互作用、Ca离子信号通路和HEDGEHOG信号通路等通路调节胃癌的发生发展。
Abstract:
Objective To investigate the expression of CPT1C in gastric cancer and its possible signaling pathway.Methods The mRNA expression RNA-seq data and clinical prognosis related data of gastric cancer data set were downloaded and preprocessed from the Tumor Genome Atlas (TCGA) database to analyze the differential expression of CPT1C gene in gastric cancer tissues and normal tissues and draw the pattern. The gastric cancer patients were divided into high expression group and low expression group according to the median of CPT1C expression. Kaplan-Meier method was used for survival analysis to explore the relationship between CPT1C expression and survival and clinicopathological features of gastric cancer patients. The relationship between CPT1C methylation and gene expression and its correlation with prognosis were analyzed by DNA methylation interactive visual database (DNMIVD). GSEA 4.0.1 software was used for gene set enrichment analysis, and the graphics of multi-GSEA enrichment analysis were drawn.Results The expression of CPT1C was significantly higher in gastric cancer than that in adjacent tissues (P=0.003). After deleting the samples with survival time <30 days in TCGA gastric cancer patients, a total of 306 samples were obtained. Patients with high CPT1C expression (n=153) had a worse prognosis (P=0.01), and in the Kaplan-Meier Plotter data analysis platform, gastric cancer patients with high CPT1C expression were also associated with poor prognosis (P<0.05). Univariate and multivariate regression analysis of TCGA gastric cancer patients suggested that high expression of CPT1C was associated with shorter survival (P=0.02), CPT1C gene expression was significantly negatively correlated with DNA promoter methylation (r=-0.33, P=6.60e-10), and hypomethylation was associated with poor prognosis (P=7.53e-03). GSEA analysis showed that CPT1C high expression samples enriched ECM receptor interaction, Ca ion signaling pathway and HEDGEHOG signaling pathway related gene sets, while CPT1C low expression samples enriched spliceosome, base excision repair and oxidative phosphorylation related gene sets.Conclusion CPT1C may be an independent prognostic factor for gastric cancer, and it may regulate the occurrence and development of gastric cancer by participating in ECM receptor interaction, Ca ion signaling pathway and HEDGEHOG signaling pathway.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]Siegel RL,Miller KD,Jemal A.Cancer statistics, 2020[J].CA Cancer J Clin,2020,70(1):7-30.[3]Cao W,Chen HD,Yu YW,et al.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chinese Medical Journal,2021,134(7):783-791.[4]Zhao H,Y Li.Cancer metabolism and intervention therapy[J].Mol Biomed,2021,2(1):5.[5]Pavlova NN,Thompson CB.The Emerging Hallmarks of Cancer Metabolism[J].Cell Metab,2016,23(1):27-47.[6]Koundouros N,Poulogiannis G.Reprogramming of fatty acid metabolism in cancer[J].Br J Cancer,2020,122(1):4-22.[7]Corn KC,Windham MA,Rafat M.Lipids in the tumor microenvironment: From cancer progression to treatment[J].Prog Lipid Res,2020,80:101055.[8]Raud B,Peter JM,Russell GJ,et al.Fatty acid metabolism in CD8(+) T cell memory: Challenging current concepts[J].Immunol Rev,2018,283(1):213-231.[9]Butler LM,Perone Y,Dehairs J,et al.Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention[J].Adv Drug Deliv Rev,2020,159:245-293.[10]Schlaepfer IR,Joshi M.CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential[J].Endocrinology,2020,161(2):bqz046.[11]Ruidas B,Sur TK,Das MC,et al.Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1[J].Breast Cancer,2022,29(4):748-760.[12]Van Weeghel M,Abdurrachim D,Nederlof R,et al.Increased cardiac fatty acid oxidation in a mouse model with decreased malonyl-CoA sensitivity of CPT1B[J].Cardiovascular Research,2018,114(10):1324-1334.[13]Rui W,Yajun C,Dongwei S,et al.Cpt1c regulated by AMPK promotes papillary thyroid carcinomas cells survival under metabolic stress conditions[J].Journal of Cancer,2017,8(18):3675-3681.[14]Wang Y,Chen Y,Guan L,et al.Carnitine palmitoyltransferase 1C regulates cancer cell senescence through mitochondria-associated metabolic reprograming[J].Cell Death Differ,2018,25(4):735-748.[15]Huizhen Z,Yongtao W,Lihuan G,et al.Lipidomics reveals carnitine palmitoyltransferase 1C protects cancer cells from lipotoxicity and senescence[J].Journal of Pharmaceutical Analysis,2021,11(3):340-350.[16]Wu B,Tao L,Yang D,et al.Development of an Immune Infiltration-Related Eight-Gene Prognostic Signature in Colorectal Cancer Microenvironment[J].Biomed Res Int,2020,2020:2719739.[17]Lanczky A,Gyorffy B.Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation[J].J Med Internet Res,2021,23(7):e27633.[18]Ding W,Chen G,Shi T.Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis[J].Epigenetics,2019,14(1):67-80.[19]Ding W,Chen J,Feng G,et al.DNMIVD: DNA methylation interactive visualization database[J].Nucleic Acids Res,2020,48(D1):D856-D862.[20]Chen T,Wu G,Hu H,et al.Enhanced fatty acid oxidation mediated by CPT1C promotes gastric cancer progression[J].J Gastrointest Oncol,2020,11(4):695-707.[21]Zhang T,Zhang Y,Liu J,et al.MicroRNA-377-3p inhibits hepatocellular carcinoma growth and metastasis through negative regulation of CPT1C-mediated fatty acid oxidation[J].Cancer Metab,2022,10(1):2.

相似文献/References:

[1]尹晓华,刘重元,黄 琳,等.胃癌中lncRNAs的研究进展[J].医学信息,2018,31(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
　YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Journal of Medical Information,2018,31(18):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[2]芮昆昆,章 波,邰小华,等.基质金属蛋白酶2与蛋白磷酸酶2A的癌性抑制因子在胃癌中的研究进展[J].医学信息,2018,31(03):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
　RUI Kun-kun,ZHANG Bo,TAI Xiao-hua,et al.The Research Progress of Matrix Metalloproteinase 2 and Cancer Inhibitor of Protein Phosphatase 2A in Gastric Cancer[J].Journal of Medical Information,2018,31(18):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
[3]段 巍.1例晚期胃癌化疗并发嗜血细胞综合征患者的护理[J].医学信息,2018,31(10):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
　DUAN Wei.Nursing Care of a Case of Advanced Gastric Carcinoma with Hemophagocytic Syndrome after Chemotherapy[J].Journal of Medical Information,2018,31(18):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
[4]潘理会,李育庄,李春辉.胃癌与高凝血状态关系的研究现状[J].医学信息,2018,31(11):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
　PAN Li-hui,LI Yu-zhuang,LI Chun-hui.Research Status of the Relationship between Gastric Carcinoma and Hypercoagulable State[J].Journal of Medical Information,2018,31(18):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
[5]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
　LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(18):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[6]林跃韩,许庆文.腹腔镜uncut Roux-en-Y吻合与传统吻合方式的研究进展[J].医学信息,2018,31(22):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
　LIN Yue-han,XU Qing-wen.Research Progress of Laparoscopic uncut Roux-en-Y Anastomosis and Traditional Anastomosis[J].Journal of Medical Information,2018,31(18):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
[7]马玉涛,石文娜,李晓林,等.免疫荧光法检测FSHR与GnRHR在胃癌组织中的分布及其共定位研究[J].医学信息,2018,31(23):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
　MA Yu-tao,SHI Wen-na,LI Xiao-lin,et al.Study on the Distribution and Co-localization of FSHR and GnRHR in Gastric Cancer Tissues by Immunofluorescence Assay[J].Journal of Medical Information,2018,31(18):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
[8]赵 静.血浆纤维蛋白原和CA724水平在胃癌患者的变化及临床意义[J].医学信息,2018,31(24):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
　ZHAO Jing.Changes and Clinical Significance of Plasma Fibrinogen and CA724 Levels in Patients with Gastric Cancer[J].Journal of Medical Information,2018,31(18):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
[9]万 芳.以贫血为首发症状的消化道恶性肿瘤临床分析[J].医学信息,2018,31(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
　WAN Fang.Clinical Analysis of Digestive Tract Malignancies with Anemia as the First Symptom[J].Journal of Medical Information,2018,31(18):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
[10]牛 悦,白建平,卢建跃.HER-2阳性胃癌的研究进展[J].医学信息,2019,32(01):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
　NIU Yue,BAI Jian-ping,LU Jian-yue.Progress in Research of HER-2 Positive Gastric Cancer[J].Journal of Medical Information,2019,32(18):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]

更新日期/Last Update: 1900-01-01